Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (April 28th Preview)
-
Obesity drug pipeline: Boehringer’s survodutide posts Phase 3 weight-loss readout
Boehringer Ingelheim disclosed Phase 3 results for survodutide, reporting 16.6% mean weight loss after about a year of treatment, using a dual-agonist approach that targets GLP-1 and glucagon pathways. The company positioned the program as aiming to improve cardiometabolic outcomes beyond existing GLP-1-based therapies, even as headline efficacy trails the strongest marketed comparators. The readout leaves unanswered questions on how patients will translate into longer-term outcomes, including durability of weight loss and cardiometabolic risk reduction. Boehringer’s next steps will likely focus on clarifying the degree of benefit across endpoints that regulators and payers weigh when evaluating obesity and cardiometabolic risk reduction therapies. For the broader field, the update underscores how the obesity market continues to shift from weight-loss magnitude alone toward cardiometabolic utility and differentiated dosing or safety profiles.
-
Oral in vivo gene editing: Intellia tees up FDA filing after Phase 3 hereditary angioedema win
Intellia reported Phase 3 success for its in vivo CRISPR medicine lonvoguran ziclumeran (lonvo-z) in hereditary angioedema (HAE), meeting the primary endpoint by reducing swelling attack rates 87% versus placebo at six months. Just over 60% of patients were attack-free during the study period, positioning the therapy as a potential functional cure approach rather than chronic prophylaxis. The company said it has initiated regulatory steps, including a rolling submission with the FDA, with the intent to bring a one-time, in-body gene-editing therapy to market. The Phase 3 HAELO study was designed around clinical attack endpoints, giving a clear efficacy signal directly tied to patient symptoms. Intellia’s result is a market-test case for whether durable in vivo editing benefits can outweigh longer-term concerns about permanent genetic changes, and it raises expectations for how regulators will evaluate safety across edited tissues over time.
-
In vivo CRISPR momentum: Intellia files with FDA after lonvo-z hits Phase 3 HAE endpoint
Intellia said its lonvo-z CRISPR therapy achieved the primary endpoint in a Phase 3 trial for hereditary angioedema and has now moved toward an FDA submission. The biotech reported an 87% reduction in attack rates versus placebo, with more than 60% of patients remaining attack-free over the assessment period. The program is designed as a one-time in vivo gene-editing approach that targets disease biology in patients’ bodies, rather than manufacturing edited cell products ex vivo. Intellia also highlighted that it began rolling submission activities, aiming to accelerate regulatory review if safety data continue to support the efficacy signal. With Vertex’s Casgevy as the only recently approved CRISPR-based medicine, lonvo-z is positioned as the next major regulatory benchmark for permanent editing therapies across rare disease indications.
-
Big Pharma M&A: Eli Lilly buys Ajax Therapeutics for up to $2.3B to bolster JAK franchise
Eli Lilly announced it will acquire Ajax Therapeutics for up to $2.3 billion in cash, adding next-generation JAK biology for myeloproliferative neoplasms. The deal gives Lilly access to AJ1-11095, a Type II JAK2 inhibitor in Phase 1 testing for myelofibrosis, with a development pathway aimed at deeper and more durable disease control than incumbent Type I therapies. Lilly framed the acquisition as a pipeline expansion using its development and commercial capabilities in blood cancers. Ajax’s early program is being tested with the goal of addressing treatment discontinuation and loss of response observed with current JAK inhibitors in long-term patient management. The transaction also reinforces Lilly’s pattern of dealmaking to replenish pipeline depth in competitive hematology markets.
-
Genome engineering platform: Gladstone’s retron recombineering extends efficient editing beyond E. coli
Gladstone Institutes researchers reported a retron-based genome editing approach that works across diverse bacterial species beyond E. coli. The study, published in Nature Biotechnology, describes “recombitrons” that pair modified retrons with single-stranded DNA binding and annealing proteins to deliver efficient, precise edits into bacterial chromosomes. In a nine-lab collaboration, the team translated the E. coli-derived system into 14 additional bacterial species spanning multiple phyla, aiming to unlock faster genetic engineering in organisms relevant to environmental, industrial, and potentially human health research. The work addresses a key limitation in bacterial engineering tool portability, offering a framework that could broaden pathogen and microbiome research capabilities that rely on high-efficiency genome editing.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.